ALKS:NASDAQ
Alkermes Plc
$46.78
arrow_upward
+1.30%(+0.60) 1D
Nov 20, 9:42:47 AM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALKS...
Open
$45.79
High
$46.79
Low
$45.79
Mkt. cap
7.86B
Avg. vol.
1.71M
Volume
110.01K
52-wk high
$55.67
52-wk low
$27.00
EPS
-$0.01
Beta
0.29
Shares outstanding
168.04M
No. of employees
2K
Open
$45.79
High
$46.79
Low
$45.79
Mkt. cap
7.86B
Avg. vol.
1.71M
Volume
110.01K
52-wk high
$55.67
52-wk low
$27.00
EPS
-$0.01
Beta
0.29
Shares outstanding
168.04M
No. of employees
2K
News stories
From web sources and news partners
Barron's
·
24 minutes ago
S&P 500 Skid Enters Seventh Day as Dow Nears Correction
ChartMill
·
1 hour ago
S&P 500 Premarket Movers Friday: Gainers and Losers
Reuters
·
48 minutes ago
SocGen sees S&P 500 ending 2027 at 8,500 on AI, earnings support
TradingView
·
55 minutes ago
S&P 500 is on track for the worst week since the April 2025 'Liberation Day' sell-off
Profile
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies, the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio. Wikipedia
About Alkermes Plc
CEORichard F. Pops | Richard F. Pops
Employees2.05K
Founded1987
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitealkermes.com